Chemotherapy
Our Clinical Trials Find out about new research studies for esophageal cancer 
|
|
|
Chemotherapy is another method of treating esophageal cancer used alone or in combination with radiation therapy and/or surgery. 1 2 3 For patients who are not candidates for surgery, chemotherapy and radiation therapy (also called chemoradiation) may be recommended without surgery.
When given alone or in combination with radiation therapy, chemotherapy may also be used to relieve symptoms of advanced cancer, such as difficulty with swallowing, and for the treatment of advanced metastatic disease that has spread to other areas of the body.
The drugs commonly used to treat esophageal cancer include 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, irinotecan, capecitabine, and mitomycin. Some of these drugs are given intravenously and some orally. This therapy is known as a systemic therapy, meaning that chemotherapy drugs travel through the blood to cells all over the body.
Investigators at Memorial Sloan-Kettering continue to identify novel therapeutic drugs to improve the care of patients with esophageal cancer. For example, the newer targeted therapy agents, including bevacizumab and cetuximab, as well as new combinations of conventional drugs are currently under investigation at the Center.
Radiation Therapy
Radiation therapy is most commonly used in combination with chemotherapy to treat esophageal cancer. It is usually administered before surgery, rather than after surgery. Radiation therapy may also be used to relieve pain, enhance swallowing, or treat other symptoms of esophageal cancer. When radiation therapy is used to treat esophageal cancer, the doctor may insert a plastic or metal tube into the esophagus to keep it open -- a procedure called stenting.
At Memorial Sloan-Kettering, we are involved in a number of clinical trials being designed and run by our own physicians. We also are involved with national trials through organizations such as the Radiation Therapy Oncology Group (RTOG) and the Cancer and Acute Leukemia Group B (CALGB), investigating new combinations of chemotherapy and radiation therapy.
Our doctors are involved in ongoing efforts to decrease the toxicity, or damage, to healthy tissues that may occur during radiation therapy for esophageal cancer. Intensity-modulated radiation therapy (IMRT) and respiratory gating are two approaches that have potential merit in decreasing toxicity to normal tissue.
IMRT is a type of 3-D radiation therapy that targets tumors with greater precision than conventional radiation therapy. Using highly sophisticated computer software and 3-D images from CT scans, the radiation oncologist can develop an individualized treatment plan that delivers high doses of radiation to cancerous tissue while sparing surrounding organs and reducing the risk of injury to healthy tissues.
Respiratory gating is another type of radiation therapy used at Memorial Sloan-Kettering to treat esophageal cancer with minimal damage to healthy tissue. Because tumors and organs in the abdomen shift during breathing, precise delivery of radiation therapy to cancerous tissue can be difficult. Respiratory gating entails the delivery of radiation treatment only at certain points during a patient's breathing cycle, when the "mobile" tumors and/or regions of the abdomen are in a specific position. This approach decreases the radiation dose to the surrounding healthy tissues. Respiratory gating is particularly important for tumors at the gastroesophageal junction, where there is a lot of motion due to breathing.